321 related articles for article (PubMed ID: 25920680)
21. Comparative DNA analysis of breast cancer by flow cytometry and image analysis.
Borgiani L; Cogorno P; Toso F; Gallo L; Buccaran G; Rovida S; Canepa M
Pathologica; 1994 Aug; 86(4):356-9. PubMed ID: 7535909
[TBL] [Abstract][Full Text] [Related]
22. Mutant p53 expression and DNA analysis in human breast cancer comparison with conventional clinicopathological parameters.
Rosanelli GP; Steindorfer P; Wirnsberger GH; Klimpfinger M; Ratschek M; Puerstner P; Auner H; Berhold A
Anticancer Res; 1995; 15(2):581-6. PubMed ID: 7763041
[TBL] [Abstract][Full Text] [Related]
23. Prognostic markers in node-negative breast cancer: a prospective study.
Kute TE; Russell GB; Zbieranski N; Long R; Johnston S; Williams H; Stackhouse C; Wilkins L; Evans I; Berry P; Rimmer K; Tucker E
Cytometry B Clin Cytom; 2004 May; 59(1):24-31. PubMed ID: 15108167
[TBL] [Abstract][Full Text] [Related]
24. TIF1γ interferes with TGFβ1/SMAD4 signaling to promote poor outcome in operable breast cancer patients.
Kassem L; Deygas M; Fattet L; Lopez J; Goulvent T; Lavergne E; Chabaud S; Carrabin N; Chopin N; Bachelot T; Gillet G; Treilleux I; Rimokh R
BMC Cancer; 2015 Jun; 15():453. PubMed ID: 26040677
[TBL] [Abstract][Full Text] [Related]
25. Clinicopathological implications of Tiam1 overexpression in invasive ductal carcinoma of the breast.
Li Z; Liu Q; Piao J; Hua F; Wang J; Jin G; Lin Z; Zhang Y
BMC Cancer; 2016 Aug; 16(1):681. PubMed ID: 27562113
[TBL] [Abstract][Full Text] [Related]
26. DNA ploidy and pS2 protein expression in breast cancer.
Ioakim-Liossi A; Karakitsos P; Aroni K; Markopoulos C; Delivelioti K; Gogas J; Kyrkou K
Cytopathology; 1997 Jun; 8(3):171-6. PubMed ID: 9202892
[TBL] [Abstract][Full Text] [Related]
27. Comparison of DNA content, S-phase fraction, and survival between medullary and ductal carcinoma of the breast.
Cook DL; Weaver DL
Am J Clin Pathol; 1995 Jul; 104(1):17-22. PubMed ID: 7611175
[TBL] [Abstract][Full Text] [Related]
28. Contralateral prophylactic mastectomy provides no survival benefit in young women with estrogen receptor-negative breast cancer.
Pesce C; Liederbach E; Wang C; Lapin B; Winchester DJ; Yao K
Ann Surg Oncol; 2014 Oct; 21(10):3231-9. PubMed ID: 25081341
[TBL] [Abstract][Full Text] [Related]
29. Tumour aneuploidy, prognostic parameters and survival in primary breast cancer.
Owainati AA; Robins RA; Hinton C; Ellis IO; Dowle CS; Ferry B; Elston CW; Blamey RW; Baldwin RW
Br J Cancer; 1987 Apr; 55(4):449-54. PubMed ID: 3580268
[TBL] [Abstract][Full Text] [Related]
30. Survival analysis between patients with invasive ductal and invasive lobular breast cancer.
Dian D; Herold H; Mylonas I; Scholz C; Janni W; Sommer H; Friese K
Arch Gynecol Obstet; 2009 Jan; 279(1):23-8. PubMed ID: 18449551
[TBL] [Abstract][Full Text] [Related]
31. Tumor response ratio predicts overall survival in breast cancer patients treated with neoadjuvant chemotherapy.
Miller M; Ottesen RA; Niland JC; Kruper L; Chen SL; Vito C
Ann Surg Oncol; 2014 Oct; 21(10):3317-23. PubMed ID: 25059788
[TBL] [Abstract][Full Text] [Related]
32. Prognostic factors in operable breast cancer treated with neoadjuvant chemotherapy: towards a quantification of residual disease.
Mombelli S; Kwiatkowski F; Abrial C; Wang-Lopez Q; de Boissieu P; Garbar C; Bensussan A; Curé H
Oncology; 2015; 88(5):261-72. PubMed ID: 25573741
[TBL] [Abstract][Full Text] [Related]
33. The value of S-phase and DNA ploidy analysis as prognostic markers for node-negative breast cancer in the Australian setting.
Wong SW; Rangan AM; Bilous AM; Boyages J; Gebski V; Benson EM
Pathology; 1999 May; 31(2):90-4. PubMed ID: 10399161
[TBL] [Abstract][Full Text] [Related]
34. Static and flow cytometric DNA analysis compared to histologic prognostic factors in a cohort of stage T2 breast cancer.
Arnerlöv C; Emdin SO; Roos G; Angström T; Bjersing L; Angquist KA; Jonsson H
Eur J Surg Oncol; 1990 Jun; 16(3):200-8. PubMed ID: 2347415
[TBL] [Abstract][Full Text] [Related]
35. Correlation of HER2 overexpression with gene amplification and its relation to chromosome 17 aneuploidy: a 5-year experience with invasive ductal and lobular carcinomas.
Nassar A; Khoor A; Radhakrishnan R; Radhakrishnan A; Cohen C
Int J Clin Exp Pathol; 2014; 7(9):6254-61. PubMed ID: 25337277
[TBL] [Abstract][Full Text] [Related]
36. [Clinical importance of histology, grading and ploidies in primary breast cancer].
Schlotter CM; Kropp S; Wichert S; Vogt U; Krieg V; Bosse U; Wassmann K
Zentralbl Gynakol; 1999; 121(8):384-8. PubMed ID: 10486881
[TBL] [Abstract][Full Text] [Related]
37. Expression of centrosomal tubulins associated with DNA ploidy in breast premalignant lesions and carcinoma.
Niu Y; Wang S; Liu T; Zhang T; Wei X; Wang Y; Jiang L
Pathol Res Pract; 2013 Apr; 209(4):221-7. PubMed ID: 23523041
[TBL] [Abstract][Full Text] [Related]
38. Prognostic value of DNA ploidy using flow cytometry in 1301 breast cancer patients: results of the prospective Multicenter Morphometric Mammary Carcinoma Project.
Bergers E; Baak JP; van Diest PJ; Willig AJ; Los J; Peterse JL; Ruitenberg HM; Schapers RF; Somsen JG; van Beek MW; Bellot SM; Fijnheer J; van Gorp LH
Mod Pathol; 1997 Aug; 10(8):762-8. PubMed ID: 9267817
[TBL] [Abstract][Full Text] [Related]
39. Time to initiation of adjuvant chemotherapy in patients with rapidly proliferating early breast cancer.
Farolfi A; Scarpi E; Rocca A; Mangia A; Biglia N; Gianni L; Tienghi A; Valerio MR; Gasparini G; Amaducci L; Faedi M; Baldini E; Rubagotti A; Maltoni R; Paradiso A; Amadori D
Eur J Cancer; 2015 Sep; 51(14):1874-81. PubMed ID: 26206258
[TBL] [Abstract][Full Text] [Related]
40. Combined analysis of vascular invasion, grade, HER2 and Ki67 expression identifies early breast cancer patients with questionable benefit of systemic adjuvant therapy.
Synnestvedt M; Borgen E; Russnes HG; Kumar NT; Schlichting E; Giercksky KE; Kåresen R; Nesland JM; Naume B
Acta Oncol; 2013 Jan; 52(1):91-101. PubMed ID: 22934555
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
